Anebulo Pharmaceuticals (ANEB)
(Delayed Data from NSDQ)
$2.95 USD
-0.17 (-5.45%)
Updated May 3, 2024 04:00 PM ET
After-Market: $3.12 +0.17 (5.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Balance Sheet
Fiscal Year End for Anebulo Pharmaceuticals, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 11 | 15 | 20 | 3 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 0 | 1 | 2 | 0 | NA |
Total Current Assets | 12 | 16 | 22 | 3 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 12 | 16 | 22 | 3 | NA |
Liabilities & Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 1 | 0 | 0 | 0 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 1 | 0 | 0 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 1 | 1 | 0 | 0 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 3 | NA |
Total Liabilities | 1 | 1 | 0 | 3 | NA |
Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 68 | 61 | 60 | 0 | NA |
Retained Earnings | -57 | -45 | -39 | 0 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 11 | 15 | 21 | 0 | NA |
Total Liabilities & Shareholder's Equity | 12 | 16 | 22 | 3 | NA |
Total Common Equity | 11 | 15 | 21 | 0 | 0 |
Shares Outstanding | 25.60 | 23.30 | 23.30 | NA | NA |
Book Value Per Share | 0.41 | 0.65 | 0.92 | 0.00 | 0.00 |
Fiscal Year End for Anebulo Pharmaceuticals, Inc falls in the month of June.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 7 | 9 | 11 | 14 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 1 | 0 | 0 |
Total Current Assets | NA | 7 | 9 | 12 | 14 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 0 | 0 | 0 |
Total Assets | NA | 8 | 9 | 12 | 14 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 0 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 1 | 1 | 1 | 1 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 1 | 1 | 1 | 1 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 69 | 68 | 68 | 68 |
Retained Earnings | NA | -62 | -60 | -57 | -55 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 6 | 8 | 11 | 13 |
Total Liabilities & Shareholder's Equity | NA | 8 | 9 | 12 | 14 |
Total Common Equity | 0 | 6 | 8 | 11 | 13 |
Shares Outstanding | 25.60 | 25.60 | 25.60 | 25.60 | 25.60 |
Book Value Per Share | 0.00 | 0.25 | 0.33 | 0.41 | 0.51 |